HMP CommunicationsFDA Approves Nivolumab for Treatment of Certain Patients With ESCC
Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.